Abstract #LBA6: Sapna Patel presented results of the P2 SWOGS1801 trial comparing adjuvant therapy (AT) (n=154) vs neoadjuvant therapy (NAT) (n=159) with pembrolizumab in patients with histologically confirmed, measurable, clinically detectable and resectable Stage IIIB-IV cutaneous,acral and mucosal melanomas without brain metastasis.
Results: After a median follow-up of 14.7 months, event free survival (EFS) was significantly higher on NAT compared to AT. 2-year EFS was 72% in the NAT arm vs49% in the AT arm. Benefit consistent across age, sex, performance status, stage, LDH, ulceration and BRAF status. Rates of adverse events were similar in both arms. In the NAT arm, available pathology reports (21%of patients) all showed complete pathologic response (0% viable tumor)on local review.
Thought leader reactions: Decidedly positive and “practice changing”for resectable stage 3-4 melanoma; neoadjuvant pembrolizumab led to significantly improved EFS vs. adjuvant with few AEs
Thought leaders also saw the data as demonstrating the broader value of neoadjuvant immunotherapy in melanoma
Encouraged by the results, some thought leaders suggested that similar comparisons should be made in other carcinomas (thoracic, uterine, bladder)
The P2 S1801 data demonstrates that neoadjuvantpembrolizumab followed by adjuvant pembrolizumab significantly improvesEFS in resectable stage 3-4 melanoma.Thought leaders in the space are very excited about the possibilities of neoadjuvant pembro (and other neoadjuvant immunotherapies) and keen to see similar trials in other cancers.
79% had reduction in disease. ORR 31%. Many responses deepen over time.
Toxicity profile was in line with prior TIL/Lifileucel data. No surprises here. Median # doses of IL-2 was 6.
Absolutely agree!… this should be available to our melanoma patients ASAP!… and paves the way for smarter cellular therapies to be designed, studied, and eventually widely disseminated
Just before I start AM clinic at @cityofhopeoc, excited to share results from #COBALT_RCC, a P1 trial of @CRISPRTX#CTX130 in #kidneycancer in the @sitcancer#PressProgram. Will present more on Thurs 5:37p at #SITC22! Thx @neerajaiims@DrBenTran@HaanenJohn#SamerSrour& co-Is! t.co/aDnhG9n92A
@montypal@cityofhopeoc@CRISPRTX@sitcancer@neerajaiims@DrBenTran@HaanenJohn@DrChoueiri@TiansterZhang@tompowles1@brian_rini@AlbigesL@Uromigos@ERPlimackMD@drenriquegrande@PGrivasMDPhD Congrats Monty! Looking forward to hearing about this exciting first-in the field study!
CAR-Ts are coming for #kidneycancer!! Congratulations @montypal and team; can’t wait to see results at #SITC22! t.co/9MrlF2yzBe
Congrats @montypal and team! Great to see CAR T therapy coming to #RCCt.co/ypRHBC89Pt
Another huge step from none other than @montypal!! CAR-Ts in #kidneycancer!Congratulations to the entire team!Looking forward to seeing the results at #SITC22! t.co/HvKeVBPyV7
@montypal you never stop to amaze me! You are brilliant & awesome! Looking forward to hearing more about this trial @sitcancer@OncoAlert@CityofHope_GU@COHMDCareers@neerajaiims@KidneyCancer@KidneyCancerDoc@NazliDizman@ZeynepZengin@LuisMezaco@crisbergerot@PauloBergerott.co/RNzOwxixQm
Artificial Intelligence (AI) has emerged as a transformative technology with the potential to revolutionize various industries, including medicine. One of the most prominent applications of AI in healthcare is the use of ChatGPT, a sophisticated language model developed by OpenAI.
When clinical trials fail to include racial and ethnic diversity into medical research, it can be harmful for large segments of the population. There is a real-world need for clinical oncology trials to adequately represent diverse racial and ethnic groups to better reflect the populations that are most likely to benefit from a drug.